General form of registration statement for all companies including face-amount certificate companies

COMMITMENTS AND CONTINGENCIES (Details Textual)

v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 06, 2018
May 17, 2017
Feb. 25, 2015
Jun. 30, 2018
Jun. 30, 2017
Mar. 31, 2018
Mar. 31, 2017
Share-based Compensation       $ 595,412 $ 251,048 $ 1,540,580 $ 1,001,950
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   25.00%          
Description Of Contribution For Formation   Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license.          
Purchase Commitment, Description On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at June 30, 2018.            
Noncontrolling Interest, Ownership Percentage by Parent   75.00%          
Royalty on Sales,Percentage       1.00%   1.00%  
Operating Leases, Future Minimum Payments Due, Next Twelve Months       $ 10,083      
Operating Leases, Future Minimum Payments, Due in Two Years       13,444      
Operating Leases, Future Minimum Payments, Due in Three Years       13,444      
Operating Leases, Future Minimum Payments, Due in Four Years       14,141      
Operating Leases, Future Minimum Payments, Due in Five Years       14,141      
Prepaid Deposits       18,131      
Bioniks JV Partner [Member]              
Due to Related Parties, Current       $ 93,309      
Exchangeable Shares [Member]              
Stock Issued During Period, Shares, Issued for Services     1,753        
Stock Transferred To Lenders     2,098        
Stock to be Reimbursed to Officers     2,134        
Proceeds from (Repayments of) Loan     $ 241,185        
Share-based Compensation     $ 210,323